Notably, treatment with soluble ACVR2B‐Fc decoy receptor has a minor impact on the heart compared to skeletal muscles64, suggesting that ACVR2B blockage is an appealing strategy for reducing cancer-induced wasting of skeletal and, to a lesser extent, cardiac muscle. This evidence concerns the gene ACVR2B and cancer.